<DOC>
	<DOCNO>NCT01138657</DOCNO>
	<brief_summary>A study compare safety efficacy adalimumab compare placebo patient active uveitis .</brief_summary>
	<brief_title>Efficacy Safety Adalimumab Patients With Active Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Subject least 18 year age . Subject diagnose noninfectious intermediate , posterior , panuveitis . Subject must active disease Baseline visit define presence least 1 follow parameter least one eye despite least 2 week maintenance therapy oral prednisone ≥ 10 mg/day ≤ 60 mg/day ( oral corticosteroid equivalent ) : Active , inflammatory , chorioretinal and/or inflammatory retinal vascular lesion ≥ 2+ anterior chamber cell ( Standardization Uveitis Nomenclature [ SUN ] criterion ) ≥ 2+ vitreous haze ( National Eye Institute [ NEI ] /SUN criterion ) Subject oral prednisone ≥ 10 mg/day ≤ 60 mg/day ( oral corticosteroid equivalent ) least 2 week prior Screening remains dose Screening Baseline visit . Subject document prior adequate response oral corticosteroid ( equivalent oral prednisone 1 mg/kg/day ) . Subjects previous , active latent tuberculosis ( TB ) . Only one TB test require allow subject study . Subjects either negative purify protein derivative ( PPD ) ( &lt; 5 mm induration ) negative QuantiFERON®TB Gold test ( interferongamma release assay ( IGRA ) equivalent ) eligible . Subjects repeat indeterminate QuantiFERON®TB Gold test ( IGRA equivalent ) result eligible . Note , one TB screen test allow require . A repeat QuantiFERON® TB Gold test ( IGRA equivalent ) permit PPD skin test positive . The TB screening test diagnostic test . In event negative TB screen test , result interpret context patient 's epidemiology , history , exam finding , etc . responsibility investigator determine patient previous , active latent tuberculosis . Under circumstance patient positive PPD result positive QuantiFERON®TB Gold test ( IGRA equivalent ) enter study . Subject isolate anterior uveitis . Subject prior inadequate response highdose oral corticosteroid Subject confirm suspect infectious uveitis , include limited infectious uveitis due TB , cytomegalovirus ( CMV ) , Human TLymphotropic Virus Type 1 ( HTLV1 ) , Whipple 's disease , Herpes Zoster virus ( HZV ) , Lyme disease , toxoplasmosis herpes simplex virus ( HSV ) . Subject serpiginous choroidopathy . Subject corneal lens opacity precludes visualization fundus likely require cataract surgery duration trial . Subject intraocular pressure ≥ 25 mmHg ≥ 2 glaucoma medication evidence glaucomatous optic nerve injury . Subject Best Corrected Visual Acuity ( BCVA ) less 20 letter ( Early Treatment Diabetic Retinopathy Study ) least one eye Baseline Visit . Subject intermediate uveitis panuveitis sign intermediate uveitis ( e.g.presence history snowbanking snowball ) symptoms and/or magnetic resonance imaging ( MRI ) finding suggestive demyelinate disease multiple sclerosis . All subject intermediate uveitis panuveitis sign intermediate uveitis ( e.g. , presence history snowbanking snowball ) must brain MRI within 90 day prior Baseline Visit . Subject previous exposure antitumor necrosis factor ( TNF ) therapy biologic therapy ( except intravitreal antivascular endothelial growth factor [ VEGF ] therapy ) potential therapeutic impact noninfectious uveitis . If enter study 1 concomitant immunosuppressive therapy , dose increase within last 28 day prior Baseline visit within follow allowable dos Baseline visit : Methotrexate ( MTX ) ≤ 25 mg per week Cyclosporine ≤ 4 mg/kg per day Mycophenolate mofetil ≤ 2 gram per day equivalent drug mycophenolate mofetil ( e.g . mycophenolic acid ) equivalent dose approve Medical Monitor . Azathioprine ≤ 175 mg per day Tacrolimus ( oral formulation ) ≤ 8 mg per day Subject receive Retisert® ( glucocorticosteroids implant ) within 3 year prior Baseline visit complication related device . Subject Retisert® ( glucocorticosteroids implant ) remove within 90 day prior Baseline visit complication related removal device . Subject receive intraocular periocular corticosteroid within 30 day prior Baseline visit . Subject proliferative severe nonproliferative diabetic retinopathy clinically significant macular edema due diabetic retinopathy . Subject neovascular/wet agerelated macular degeneration Subject abnormality vitreoretinal interface ( i.e. , vitreomacular traction , epiretinal membrane , etc . ) potential macular structural damage independent inflammatory process . Subject severe vitreous haze precludes visualization fundus Baseline visit . Subject receive Ozurdex® ( dexamethasone implant ) within 6 month prior Baseline visit . Subject receive intravitreal antiVEGF therapy within 45 day Baseline visit Lucentis® ( ranibizumab ) Avastin® ( bevacizumab ) within 60 day Baseline visit antiVEGF Trap ( aflibercept ) . Subject receive intravitreal methotrexate within 90 day prior Baseline visit Subject systemic carbonic anhydrase inhibitor within 1 week prior Screening visit . Subject macular edema sign uveitis . Subject history scleritis . Subject intolerance highdose oral corticosteroid ( equivalent oral prednisone 1 mg/kg/day 60 80 mg/day ) . Subject cyclophosphamide within 30 day prior Baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>inflammation uvea</keyword>
</DOC>